Rosiglitazone REMS Program

Rosiglitazone Risk Evaluation and Mitigation Strategy (REMS) Program

What is the Rosiglitazone REMS (Risk Evaluation and Mitigation Strategy)?

The Rosiglitazone REMS is a training program designed to inform prescribers of the current state of knowledge concerning the cardiovascular risk of rosiglitazone-containing medicines. This program is required by The Food and Drug Administration (FDA) to ensure the benefits of rosiglitazone containing medicines outweigh the risks.

Approved Rosiglitazone Products and Manufacturers